AngioDynamics (NASDAQ:ANGO) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.
Several other brokerages have also weighed in on ANGO. Craig Hallum lowered AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Zacks Investment Research raised AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Monday, January 22nd. Finally, TheStreet lowered AngioDynamics from a “b-” rating to a “c” rating in a report on Tuesday, January 2nd. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $18.60.
Shares of NASDAQ:ANGO opened at $17.25 on Friday. AngioDynamics has a fifty-two week low of $14.80 and a fifty-two week high of $18.85. The stock has a market capitalization of $633.85, a P/E ratio of 23.96, a PEG ratio of 1.60 and a beta of 1.00. The company has a quick ratio of 1.65, a current ratio of 2.56 and a debt-to-equity ratio of 0.17.
Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in AngioDynamics in the 3rd quarter worth about $143,000. Crossmark Global Holdings Inc. bought a new position in AngioDynamics in the 4th quarter worth about $172,000. Trexquant Investment LP bought a new position in AngioDynamics in the 3rd quarter worth about $175,000. Teacher Retirement System of Texas bought a new position in AngioDynamics in the 4th quarter worth about $201,000. Finally, MetLife Investment Advisors LLC bought a new position in AngioDynamics in the 4th quarter worth about $297,000. Institutional investors and hedge funds own 97.09% of the company’s stock.
WARNING: This report was published by WKRB News and is owned by of WKRB News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.wkrb13.com/2018/04/01/bidaskclub-upgrades-angiodynamics-ango-to-buy.html.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.